MyDosageBeta
Goals/01
Guided intelligence brief

Weight loss.

GLP-1 and dual-agonist incretins have the strongest human RCT evidence of any class on this index for weight reduction, appetite suppression, and glycemic control. Compounded routes carry separate quality and regulatory considerations.

01Mechanisms

How this class moves the outcome.

01

Incretin receptor agonism

GLP-1 (and GIP / glucagon on dual / tri-agonists) slow gastric emptying, suppress appetite centrally, and improve glycemic control — the dominant weight-reduction pathway in this class.

02

Central appetite regulation

Direct hypothalamic action on satiety circuits reduces caloric intake independent of conscious restraint — the mechanism most users actually feel.

03

Energy expenditure (dual / tri-agonists)

Glucagon-arm agonism on newer compounds (retatrutide) adds a modest thermogenic component on top of intake suppression.

02Candidate compounds

Ranked by human-evidence strength.

  1. 01

    Tirzepatide

    Mounjaro

    Dual incretin receptor agonist with larger weight reduction than semaglutide in head-to-head trials.

    GIP / GLP-1 dual agonistt½ ~5 daysHuman RCT
    AHuman RCT evidence
    6.5EIS™ · Moderate
    Open full brief →
  2. 02

    Semaglutide

    Ozempic

    Long-acting GLP-1 analogue approved for type-2 diabetes and chronic weight management. The most rigorously studied peptide on this index.

    GLP-1 receptor agonistt½ ~7 daysHuman RCT
    AHuman RCT evidence
    8.0EIS™ · Strong
    n=4 indexed studies
    Open full brief →
  3. 03

    Retatrutide

    LY3437943

    Triple-receptor agonist in late-stage trials with ~24% mean weight loss at 48 weeks. Not yet approved.

    GIP / GLP-1 / glucagon triple agonistt½ ~6 daysHuman RCT
    AHuman RCT evidence
    6.5EIS™ · Moderate
    Open full brief →
  4. 04

    Liraglutide

    Saxenda

    Daily GLP-1 analogue, first-in-class for chronic weight management. Older and shorter-acting than semaglutide.

    GLP-1 receptor agonistt½ ~13 hHuman RCT
    AHuman RCT evidence
    6.5EIS™ · Moderate
    Open full brief →
  5. 05

    Cagrilintide

    AM833

    Long-acting amylin analogue investigated alone and combined with semaglutide (CagriSema) for weight loss.

    Amylin analoguet½ ~7 daysHuman RCT
    AHuman RCT evidence
    6.6EIS™ · Moderate
    Open full brief →
03Human evidence

What the human data actually shows.

Brief composition
Evidence composition5 entries
RCT 5 Obs 0 Pre 0

Each bar is the proportion of candidates on this brief at that evidence tier. RCT first, observational second, preclinical and anecdotal labeled and never inflated.

See full methodology →
Outcome matrix
Total body weight reduction (52 wk)
Multi-RCT, dose-dependent, >15% on tirzepatide.
Agrade
9.2
Glycemic control / HbA1c
Approved indication, robust.
Agrade
9.0
Cardiovascular event reduction
Strong for semaglutide (SELECT); class-extrapolation cautious.
Bgrade
7.4
Appetite suppression / food noise
Consistent across the class.
Agrade
8.8
Sustained weight maintenance off-drug
Most data shows partial regain on discontinuation.
Cgrade
4.0
Top studies behind this brief

Indexed human trials and reviews driving the candidate rankings above. Sorted by study type, then recency.

6 shown
04Risks & limitations

Where this class can hurt you.

Top class-level risks
  • GI side effects (nausea, vomiting, constipation) — dose-titration dependent.
  • Rare but documented pancreatitis and gallbladder events.
  • Lean-mass loss without resistance training — body composition is a separate goal.
  • Compounded products carry sterility, identity, and dosing-accuracy risk distinct from the approved medicine.
What we still don't know
  • Long-term (>5 year) safety data is still accumulating for newer dual / tri-agonists.
  • Body composition (lean-mass preservation, recomp) is its own goal — GLP-1 is not the primary lever there.
  • Off-label compounded products are not equivalent to regulator-approved medicine.
05Comparison

Decide between candidates.

Put the top 4 candidates side by side.

Mechanism · half-life · routes · evidence tier · safety signals. A decision matrix, not a leaderboard.

Open the matrix →Ask the assistant
06Consensus engine

Current scientific consensus.

8.6/ 10
Overall confidence
Strong
Human evidence
Strong
Risk profile
Moderate
Strongest supported
  • Weight reduction at 52 weeks
  • HbA1c reduction
  • Reduced cardiovascular events (semaglutide)
Weak / unclear claims
  • Lean-mass-only loss
  • Permanent metabolic 'reset' off-drug
Major unknowns
  • Multi-decade safety
  • Optimal off-ramp protocol
  • Pediatric long-term outcomes
Editorial outlook

"The most robust therapeutic class on this index. Mature for adult metabolic disease; durability and discontinuation strategy remain open."

07Long-term outlook

Where this is heading.

The most robust therapeutic class on this index. Mature for adult metabolic disease; durability and discontinuation strategy remain open.

We re-grade this brief quarterly. Confidence and outcome grades shift as new RCTs publish, safety data accumulates, and replication efforts read out. Changes are logged publicly on the evidence changelog.

Methodology →Changelog →Safety surface →
06Canonical, evidence-anchored

Matched protocol templates.

Matching templates…